mitoxantrone has been researched along with Leukemia, Lymphocytic, Chronic, T Cell in 4 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It suggests that a chemotherapy backbone prevents efficient alemtuzumab dosing and confirms that intravenous alemtuzumab is to be preferred over its s." | 2.90 | New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. ( Bahlo, J; Cramer, P; Dürig, J; Eichhorst, B; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kreuzer, KA; Mayer, P; Oberbeck, S; Pflug, N; Robrecht, S; Schrader, A; Seiler, T; Stilgenbauer, S; Westermann, A; Zenz, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pflug, N | 2 |
| Cramer, P | 2 |
| Robrecht, S | 1 |
| Bahlo, J | 1 |
| Westermann, A | 2 |
| Fink, AM | 2 |
| Schrader, A | 1 |
| Mayer, P | 1 |
| Oberbeck, S | 1 |
| Seiler, T | 1 |
| Zenz, T | 1 |
| Dürig, J | 1 |
| Kreuzer, KA | 1 |
| Stilgenbauer, S | 2 |
| Eichhorst, B | 2 |
| Hallek, M | 2 |
| Herling, M | 2 |
| Hopfinger, G | 2 |
| Busch, R | 1 |
| Weit, N | 1 |
| Reinart, N | 1 |
| Winkler, D | 1 |
| Fingerle-Rowson, G | 1 |
| Döhner, H | 1 |
| Kandler, G | 1 |
| Fujiwara, K | 1 |
| Fukuhara, T | 1 |
| Kitano, H | 1 |
| Okazaki, T | 1 |
| Ma, SY | 1 |
| Au, WY | 1 |
| Chim, CS | 1 |
| Lie, AK | 1 |
| Lam, CC | 1 |
| Tse, E | 1 |
| Leung, AY | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia[NCT01186640] | Phase 2 | 16 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia[NCT00278213] | Phase 2 | 17 participants (Anticipated) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for mitoxantrone and Leukemia, Lymphocytic, Chronic, T Cell
| Article | Year |
|---|---|
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Topics: Adult; Aged; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; | 2019 |
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pr | 2013 |
Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2004 |
1 other study available for mitoxantrone and Leukemia, Lymphocytic, Chronic, T Cell
| Article | Year |
|---|---|
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cladribine; Combined Moda | 2014 |